Forte Biosciences secures shareholder approval for 1-for-25 reverse split effective Aug 28

Forte Biosciences, Inc.

Reverse stock split ratio set at 1-for-25; effective Aug 28, 2024, with new CUSIP 34962G 208.
Stockholders approved amendment to effect reverse split (26.7M for, 2.1M against).
Amended 2021 Equity Incentive Plan approved (17.3M for, 6.9M against); adds up to 8.5M new shares plus up to 1.1M from prior plans.
Class I directors elected: Barbara K. Finck, M.D. (18.8M for), Donald A. Williams (15.4M for), Stephen K. Doberstein (15.1M for).
KPMG LLP ratified as independent auditor for FY2024 with 28.8M votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.